Alteogen Inc
196170
Company Profile
Business description
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
Contact
62, Yuseong-daero 1628beon-gil
Yuseong-gu
Daejeon34054
KORT: +82 423848780
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
157
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.00 | 15.60 | 0.17% |
| CAC 40 | 8,062.58 | 49.44 | -0.61% |
| DAX 40 | 24,703.12 | 255.94 | -1.03% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,126.78 | 68.57 | -0.67% |
| HKSE | 26,455.53 | 31.98 | -0.12% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,705.34 | 285.76 | -0.54% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,796.86 | 143.15 | -2.06% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,127.14 | 13.50 | 0.33% |